CHICAGO--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of studies highlighting data involving the Company’s lead product, Tarceva®, presented during the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 1-5 in Chicago, IL. Tarceva is currently approved as a monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, and in combination with gemcitabine chemotherapy for the first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer.
